LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later.

Ekpanyapong, Sirina / Bunchorntavakul, Chalermrat / Reddy, K Rajender

Journal of viral hepatitis

2021  Volume 29, Issue 1, Page(s) 4–20

Abstract: ... and chronic manifestation of cholangiopathy, has been observed in COVID-19. The pathogenesis of liver ... from the EAST and the WEST. Published studies and regional society guidelines from the EAST and the WEST were ... manifestations in coronavirus disease 2019 (COVID-19) have been described and unique considerations raised ...

Abstract Globally, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause for significant morbidity and mortality. Since the start of the pandemic, several hepato-biliary manifestations in coronavirus disease 2019 (COVID-19) have been described and unique considerations raised. The review aims to summarize the pathogenesis and hepato-biliary manifestations in COVID-19 and discuss the similarities, contrasting features and disease-specific management across a range of hepato-biliary diseases from the EAST and the WEST. Published studies and regional society guidelines from the EAST and the WEST were comprehensively reviewed and summarized. A wide range of hepato-biliary manifestations, including the infrequent and chronic manifestation of cholangiopathy, has been observed in COVID-19. The pathogenesis of liver injury is multifactorial and with scant evidence for a direct SARS-CoV-2 infection of the liver. Patients with non-alcoholic fatty liver disease, cirrhosis, and liver cancer are potentially at increased risk for severe COVID-19, and there are unique considerations in chronic hepatitis B or C, hepatocellular carcinoma, and in those immunosuppressed such as autoimmune hepatitis or liver transplant recipients. With the surges in SARS-CoV-2 infection, liver transplant activity has variably been impacted. Preliminarily, SARS-CoV-2 vaccines appear to be safe in those with chronic liver disease and in transplant recipients, while emerging data suggest the need for a third dose in immunosuppressed patients. In conclusion, patients with chronic liver disease, particularly cirrhosis, and liver transplant recipients, are vulnerable to severe COVID-19. Over the past year, several unique considerations have been highlighted across a spectrum of hepato-biliary diseases. Vaccination is strongly recommended for those with chronic liver disease and liver transplant recipients.
MeSH term(s) COVID-19 ; COVID-19 Vaccines ; Humans ; Liver Diseases/epidemiology ; SARS-CoV-2
Chemical Substances COVID-19 Vaccines
Language English
Publishing date 2021-08-12
Publishing country England
Document type Journal Article ; Review
ZDB-ID 1212497-7
ISSN 1365-2893 ; 1352-0504
ISSN (online) 1365-2893
ISSN 1352-0504
DOI 10.1111/jvh.13590
Shelf mark
Zs.A 4119: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top